Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
134
-
Total 13F shares, excl. options
-
100,546,584
-
Shares change
-
-3,252,360
-
Total reported value, excl. options
-
$340,303,134
-
Value change
-
-$8,611,368
-
Put/Call ratio
-
2.03%
-
Number of buys
-
62
-
Number of sells
-
-60
-
Price
-
$3.38
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q1 2021
161 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q1 2021.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 134 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 100,546,584 shares
of 236,234,693 outstanding shares and own 42.56% of the company stock.
Largest 10 shareholders include STATE STREET CORP (17,044,176 shares), BlackRock Inc. (12,368,986 shares), VANGUARD GROUP INC (11,692,154 shares), WELLINGTON MANAGEMENT GROUP LLP (10,838,165 shares), Nantahala Capital Management, LLC (5,150,819 shares), SATTER MANAGEMENT CO., L.P. (4,652,561 shares), MORGAN STANLEY (3,340,709 shares), GOLDMAN SACHS GROUP INC (2,778,687 shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2,668,029 shares), and GEODE CAPITAL MANAGEMENT, LLC (2,598,807 shares).
This table shows the top 134 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.